Anonymous
Guest
Anonymous
Guest
What's Little Ricky doing about the revenue gap? Maybe we will be selling necklaces! It would be so funny if it wasn't true.
He's not doing much other than making the rounds at NY Fashion Week.
What's Little Ricky doing about the revenue gap? Maybe we will be selling necklaces! It would be so funny if it wasn't true.
Well, back to vacation mode then, "Boots and pants and boots and pants and boots and pants..."
He's not doing much other than making the rounds at NY Fashion Week.
When Humira goes off patent, what will Abbvie have to replace all of that lost revenue? I imagine that there must be a plan in place to adjust operating costs accordingly.
I believe it was called Viekira Pak...
Just focus on selling more humira...someone needs to pay for a very fancy wedding #sugardaddy #birkincartierrolex #truelove #seeking arrangement #prenuptial #sucka
Amgen announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.
Your manager appears to be very intelligent. Side effect of not drinking the kool-aid...one actually sounds reasonable.
Well, my manager says that we are safer in Derm. Rhem is the least safe.
To hedge against biosimilars for its $10 billion blockbuster Humira, AbbVie has 5 drugs in 8 Phase II trials.
Please just sell more...i need another bentley ASAP!
That does nothing for the job security of all of the salespeople. If any of those drugs ever make it to market, it won't be in the next five years.